The gonadotrophin resistant ovary syndrome: a curable disease?
A patient with the resistant ovary syndrome is reported. It is suggested that lack of synchronization between steroidogenesis in the granulosa and theca cells is responsible for the (acquired) occurrence of this syndrome. Feedback inhibition of pituitary gonadotrophin secretion was achieved by exogenously administered ovarian steroid hormones. All protein and steroid hormone levels returned to normal and spontaneous ovulatory cycles returned after withdrawal of medication. It is concluded that the so called "resistant ovary syndrome" is not an irreversible process.
D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008525:Medroxyprogesterone / Q000627:therapeutic use; D010049:Ovarian Diseases / Q000097:blood / Q000188:drug therapy*; D011374:Progesterone / Q000097:blood; D013577:Syndrome
D004997:Ethinyl Estradiol; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008525:Medroxyprogesterone